EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma

Ludek Pour, Ilina Micheva, Ganna Usenko, Gabor Mikala, Tamas Masszi, Kameliya Simeonova, Marcus Thuresson, Gunilla Huledal, Stefan Norin, Nicolaas A Bakker, Jiri Minarik

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2024.02.012 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Ludek Pour und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Hauptthemen laut MEDLINE: Multiple Myeloma, Cross-Over Studies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaCross-Over StudiesHumansMaleFemaleMiddle AgedAgedPhenylalanineAdultMelphalanNeoplasm Recurrence, LocalAdministration, IntravenousAged, 80 and overTreatment OutcomeInfusions, Intravenous

Stichwörter der Autor:innen

CatheterCentral venousMelphalanPeripheral venous

Substanzen

melflufenPhenylalanineMelphalan

Autor:innen und Institutionen

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Hematology Clinic, University Hospital "St. Marina," Medical University, Varna, Bulgaria.
  • City Clinical Hospital #4 of Dnipro, Dnipro, Ukraine.
  • Department of Hematology and Stem Cell Transplantation, National Institute for Hematology and Infectious Diseases, South Pest Central Hospital, Budapest, Hungary.
  • Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
  • Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria.

Zitieren

APA

Pour, L., Micheva, I., Usenko, G., Mikala, G., Masszi, T., Simeonova, K., Thuresson, M., Huledal, G., Norin, S., Bakker, N. A., & Minarik, J. (2024). PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.02.012

Vancouver

Pour L, Micheva I, Usenko G, Mikala G, Masszi T, Simeonova K, et al. PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.02.012

BibTeX
@article{Pour2024,
  author = {Pour, Ludek and Micheva, Ilina and Usenko, Ganna and Mikala, Gabor and Masszi, Tamas and Simeonova, Kameliya and Thuresson, Marcus and Huledal, Gunilla and Norin, Stefan and Bakker, Nicolaas A and Minarik, Jiri},
  title = {PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2024.02.012}
}
Kostenlos starten →